Filed with ASX · · 3 pages · English
Starpharma Holdings Limited has announced that it has secured majority ownership of Petalion Therapeutics, increasing its equity interest from a minority stake to a controlling share. This acquisition allows Starpharma to lead the development of a targeted oncology program utilizing its DEP® platform, aligning development priorities with its broader strategy. Starpharma will contribute funds and resources to advance the program, while Medicxi will maintain a strategic partnership and board representation. The transaction is seen as a disciplined investment that enhances Starpharma's oncology portfolio and decision-making capabilities.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ASX Announcement Starpharma secures majority ownership of Petalion Starpharma to lead development of the FAP-targeted DEP® program, with Medicxi remaining a strategic partner and substantial shareholder • Starpharma has increased its equity interest in Petalion Therapeutics from 22.5% to 66%,...
Starpharma Holdings Limited on 6ix
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma